Agenda

Keynote Speaker:

Alan List, M.D., President and Chief Executive Officer of Moffitt Cancer Center in Tampa, FL. Dr. List is internationally recognized for his many contributions in the development of novel, more effective treatment strategies for myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML).

 

 

 

Friday, July 12, 2019

10:30 am - 11:00 am EST
Check-In
11:00 am - 11:05 am EST
Welcome and Introductions

Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI
Naoko Takebe, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI

11:05 am - 11:20 am EST
Opening Keynote

Tom Misteli, Ph.D., Center for Cancer Research, NCI

11:20 am - 12:00 pm EST
Keynote Lecture: The Role of Innate Immunity in MDS Pathogenesis

Alan List, M.D., Moffit Cancer Center

12:00 pm - 12:25 pm EST
Session 1: Introduction to MDS

Moderator: Naoko Takebe, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI

WHO MDS Classification
Katherine Calvo, M.D., Ph.D., Clinical Center, NIH

Overview of MDS Standard Therapy
Catherine Lai, M.D., Lombardi Cancer Center

12:25 pm - 01:30 pm EST
Session 2: From Laboratory to Clinic

Moderator: Peter Aplan, M.D., Center for Cancer Research, NCI

Somatic and Germ Line Mutations in AML
Paul Liu, M.D., Ph.D., National Human Genome Research Institute, NIH

Current Status and Advances in MRD Measurement
Christopher Hourigan, M.D., D.Phil., National Heart, Lung, and Blood Institute, NIH
Laura Dillon Ph.D., National Heart, Lung, and Blood Institute, NIH

Preclinical Myeloid Leukemia Models
Peter Aplan, M.D., Center for Cancer Research, NCI

Novel HMAs and Combinations
Steven Grant, M.D., Virginia Commonwealth University

CTEP AML/MDS Precision Medicine Initiative
Rich Little, M.D., Division of Cancer Treatment and Diagnosis, NCI

01:30 pm - 02:00 pm EST
BREAK
02:00 pm - 03:00 pm EST
Session 2: From Laboratory to Clinic (continued)

Moderator: Nirali Shah, M.D., Center for Cancer Research, NCI

Heterogeneity in Refractory AML
Michael Gottesman, M.D., Center for Cancer Research, NCI

Targeting HMA Refractory MDS
Daniel Larson, Ph.D., Center for Cancer Research, NCI

Strategies to Enhance Effects of Cellular Immunotherapy
Jack Shern, M.D., Center for Cancer Research, NCI

NK Cell Therapy for Myeloid Leukemia
Kate Stringaris, M.D., Ph.D., National Heart, Lung and Blood Institute, NIH

Chemotherapy Induced AML in Modern Era
Lindsay Morton, Ph.D., Division of Cancer Epidemiology and Genetics, NCI

03:00 pm - 04:20 pm EST
Session 3: Active Treatment Protocols

Moderator: Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI

DCTD Phase 1 Program
Geraldine O’Sullivan, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI

Clofarabine and Bortezomib Phase 1 Study
Naoko Takebe, M.D., Ph.D., Division of Cancer Treatment and Diagnosis, NCI
Sabrina Khan, M.D., MPH, Center for Cancer Research, CCR

CSF1R Blockade
Rosandra Kaplan, M.D., Center for Cancer Research, NCI

MUD RIC Transplant for Hematologic Malignancy
Steven Pavletic, M.D., M.S., Center for Cancer Research, NCI

Haplo-Identical Donor Transplant for Hematologic Malignancy
Christopher Kanakry, M.D., Center for Cancer Research, NCI

CAR-T Cells for Acute Leukemia
Nirali Shah, M.D., Center for Cancer Research, NCI

04:20 pm - 05:00 pm EST
Session 4: Inherited Leukemia Protocols

Moderator: Lea Cunningham, M.D., National Human Genome Research Institute, NCI

Allogeneic Transplant for GATA2 Mutation
Mark Parta, Ph.D., National Institute of Allergy and Infectious Diseases, NIH

RUNX1 Clinic and Transplant Protocols
Lea Cunningham, M.D., National Human Genome Research Institute, NCI

Other Inherited Leukemias
Lisa McReynolds, M.D., Ph.D., Division of Cancer Epidemiology and Genetics, NCI